Neurophet, the Korean medical AI company, said on Monday that it has signed an exclusive agreement with Clairvo Technologies to sell Neurophet Aqua, its flagship neurological degenerative disease diagnosis assistant software, in Japan.
Earlier in March, Neurophet received medical device certification for Neurophet Aqua from Japan’s Ministry of Health, Labor and Welfare (MHLW). Accordingly, Neurophet will carry out sales, marketing and promotional activities with Clairvo to sell Neurophet Aqua in Japan, the Korean company said.
Neurophet Aqua quantitatively analyzes brain MRI with AI technology to detect brain atrophy and white matter degeneration observed in neurodegenerative diseases such as Alzheimer’s disease and vascular dementia.
The patient’s brain image is divided into 35 major regions and brain volume atrophy, brain aging, and white matter degeneration analysis are compared with normal people of the same age and gender and compiled into a report.
With high analysis accuracy, Neurophet Aqua significantly reduced the software analysis time from 8 to 24 hours on competing technologies to just 5 minutes, according to the company.
Brain image analysis is possible regardless of race, age, and gender, and consistent results are derived from images from different MRI devices such as GE, Philips, and Canon.
Clairvo is owned by the Marubeni Group, one of Japan’s top five general companies. It imports medical devices from the United States and Taiwan and distributes them in the Japanese market.
“Korean medical AI technology is recognized not only in Japan but worldwide as it stands out at international conferences,” said Clairvo CEO Riichi Yamada. “We expect Neurophet Aqua to be in high demand in the Japanese medical market.”
Neurophet CEO Been Jun-kil said that through this contract with Clairvo, the company has found a business partner that can sell and distribute directly in the largest medical device market in Asia.
“We plan to accelerate efforts to focus on global markets so that we can expand product sales in overseas markets such as the US, Europe and Southeast Asia in the future,” he said.
